Unusually active option classes on open March 30th » 09:4003/3003/30/20
ABT, NAT, GME, APT, BMY, UUP, JNJ
Unusual total active…
Big Lots withdraws Q1, FY20 guidance issued on February 27 » 09:0203/3003/30/20
Big Lots provided an…
Zoom Video users up 'staggering' 378% versus last year, says JPMorgan » 08:5403/3003/30/20
According to Apptopia…
According to Apptopia data, daily active users and monthly active users on Zoom Cloud Meetings App as of March 22 was 15.3M and 28M, respectively, JPMorgan analyst Sterling Auty tells investors in a research note. This represents a "staggering" 378% increase in daily active users and 186% increase in monthly active users when comparing to the same time in 2019, adds the analyst. Auty says Zoom is experiencing significant uptake in terms of usage and application downloads during the COVID-19 crisis. The analyst, who acknowledges that the stock has had a tremendous run year-to-date and likely could see a sell the news reaction at whatever time we move past the current COVID-19 impacts, believes the pandemic has created a wake-up call in terms of businesses understanding what is possible for remote work set ups that will likely change business behavior going forward. Auty keeps an Overweight rating on Zoom Video.
Altimmune, UAB collaborate on development of COVID-19 vaccine » 07:3703/3003/30/20
Altimmune announced that…
Trade Desk put volume heavy and directionally bearish » 11:5503/2703/27/20
Bearish flow noted in…
Bearish flow noted in Trade Desk with 2,626 puts trading, or 1.0x expected. Most active are Apr-20 140 puts and Apr-20 145 puts, with total volume in those strikes near 1,600 contracts. The Put/Call Ratio is 2.64, while ATM IV is up over 9 points on the day. Earnings are expected on May 7th.
Alpha Pro Tech call volume above normal and directionally bullish » 11:0503/2703/27/20
Bullish option flow…
Bullish option flow detected in Alpha Pro Tech with 8,314 calls trading, 1.9x expected, and implied vol increasing over 3 points to 185.79%. 3/27 weekly 10 calls and Apr-20 15 calls are the most active options, with total volume in those strikes near 3,000 contracts. The Put/Call Ratio is 0.07. Earnings are expected on May 6th.
Fly Intel: Pre-market Movers » 09:1403/2703/27/20
WW, SCWX, GME, KBH, ALT, OCGN, QFIN, LULU, TXMD, HTZ, GPS
Check out this morning's…
Altimmune plans to begin Phase 1 trial of ALT-801 in 2020 » 07:1903/2703/27/20
The company said,…
The company said, "The Company acquired Spitfire Pharma, Inc. including the product candidate ALT-801, a potent GLP-1/Glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis. ALT-801 is a peptide-based therapeutic candidate with balanced agonist activity on the GLP-1 and glucagon receptors and a differentiated PK profile to improve tolerability. ALT-801 is designed to treat obesity, the basic underlying cause of NASH, the most severe form of non-alcoholic fatty liver disease. The Company is preparing for a Phase 1 clinical trial anticipated to begin in 2020."
Altimmune plans to begin animal testing of AdCOVID in 2Q20 » 07:1703/2703/27/20
The company said,…
The company said, "Utilizing our proprietary intranasal vaccine technology, the Company began development of AdCOVID, a vaccine candidate to protect against COVID-19. We believe, our vaccine technology is particularly well positioned to respond to pandemic respiratory infections as it combines intranasal dosing, a broad, rapid immune response and room temperature stability with avoidance of cold chain shipping requirements, making it easier to distribute across communities. The Company designed and created the vaccine candidate in February and plans to begin animal testing in Q2 2020. The Company is engaged in discussions with a number of organizations who are addressing this crisis, including The United States Medical Countermeasures Task Force, The World Health Organization, academia, and other institutions engaged in the effort."
Altimmune reports FY19 EPS ($1.60), one est. ($1.52) » 07:1703/2703/27/20
Reports FY19 revenue…
Reports FY19 revenue $5.8M, one est. $5.98M. "2019 was a productive year for the Company with the acquisition of ALT-801, a supplemental award for the development of NasoShield from BARDA, and the advancement of ALT-702 as a preclinical program," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "However, we all find ourselves in a very different world in 2020 with the COVID-19 global pandemic causing substantial disruption to many of our lives. We face an unprecedented time, which will require companies, organizations, academic institutions, and governments to come together as a united front against this pandemic. At Altimmune, we believe we can leverage our intranasal vaccine technology platform and experience with both influenza and anthrax to rapidly develop a COVID-19 vaccine candidate. Our entire Company is working tirelessly to address this crisis as we progress our vaccine candidate for COVID-19 towards the initiation of a Phase 1 clinical trial as early as Q3 of this year. We believe our vaccine platform has the potential to offer specific and substantial benefits to address a pandemic situation, and we will continue to press forward in our effort to address this challenge."